The Her2/neu protein expression has been associated with clonal T lymphocytes in breast cancer patients (Peoples et al, 1995; Goodell et al, 2008; Wiech et al, 2008), and strategies of immunotherapy eliciting antibody and CD8-positive T-cell responses against Her2/neu are being discussed (Disis et al, 2002). Here, ERBB2 is linked to breast cancer.